Market Place
Sourcing Support
Madrigal Pharmaceuticals to Attend 3 Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Madrigal`s MASH drug Rezdiffra `blew away` expectations in Q3
31 Oct 2024 //
FIERCE PHARMA
Madrigal Pharmaceuticals Reports Q3 2024 Results & Updates
31 Oct 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals to Present Rezdiffra™ Abstracts at AASLD
30 Oct 2024 //
GLOBENEWSWIRE
Madrigal Completes Enrollment Of Study On Resmetirom In NASH
21 Oct 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals To Release Q3 Results On Oct 31
18 Oct 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Attends H.C. Wainwright MASH Conference
02 Oct 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as SVP
01 Oct 2024 //
GLOBENEWSWIRE
Madrigal Publishes Quality Of Life Results From Ph 3-NASH trial
30 Sep 2024 //
GLOBENEWSWIRE
Madrigal Pharma to Participate in Morgan Stanley Global Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals To Participate In Morgan Stanley Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
Madrigal to target digestive scientific meetings to kick-start MASH growth
12 Aug 2024 //
FIERCE PHARMA
Madrigal To Target Scientific Meetings For MASH Growth
12 Aug 2024 //
FIERCE PHARMA
Madrigal Pharma Set For Market Lead With Rezdiffra Success In MASH Market
11 Aug 2024 //
EXPRESSPHARMA
Madrigal Pharmaceuticals Reports Q2 2024 Results And Corporate Updates
07 Aug 2024 //
GLOBENEWSWIRE
Madrigal`s Rezdiffra off to strong start, but `bumpiness` is coming: analyst
07 Aug 2024 //
FIERCE PHARMA
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
02 Aug 2024 //
GLOBENEWSWIRE
Madrigal Pharma To Release Q2 2024 Results On August 7
24 Jul 2024 //
GLOBENEWSWIRE
Madrigal Presents MAESTRO-NASH Data On Rezdiffra™ At EASL Congress
06 Jun 2024 //
GLOBENEWSWIRE
Lilly pads tirzepatide`s MASH win with detailed fibrosis data
06 Jun 2024 //
FIERCE PHARMA
Madrigal Pharma: Participating At Goldman Sachs Healthcare Event
05 Jun 2024 //
GLOBENEWSWIRE
Viking`s MASH drug scores where Madrigal`s didn`t
05 Jun 2024 //
FIERCE BIOTECH
Madrigal`s Rezdiffra Data At EASL On NASH/MASH And Health Economics
29 May 2024 //
GLOBENEWSWIRE
Madrigal builds launch infrastructure for MASH drug Rezdiffra
08 May 2024 //
FIERCE PHARMA
Madrigal Pharmaceuticals Q1 2024 Results And Corporate Updates
07 May 2024 //
GLOBENEWSWIRE
Madrigal Statement on the Passing of Dr. Stephen Harrison
24 Apr 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals to Report Q1 2024 Results, Host Webcast on May 7, 2025
23 Apr 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals stock rated Underperform by BofA
22 Apr 2024 //
INSVESTING
Madrigal Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Apr 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals launches Rezdiffra in the US
09 Apr 2024 //
GLOBENEWSWIRE
Docs sing praises of Madrigal`s Rezdiffra, predict rapid uptake
08 Apr 2024 //
FIERCE PHARMA
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2024 //
GLOBENEWSWIRE
After MASH nod, Madrigal plots $600M stock sale to support launch
19 Mar 2024 //
FIERCE PHARMA
Madrigal Pharmaceuticals Announces Proposed Public Offering
18 Mar 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Announces Pricing of Upsized $600M Public Offering
18 Mar 2024 //
GLOBENEWSWIRE
FDA approves Madrigal drug as first treatment for common NASH liver disease
15 Mar 2024 //
CNBC
Madrigal to grapple with lack of awareness about NASH
12 Mar 2024 //
ENDPTS
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Announces EMA Validation of its MAA for Resmetirom
05 Mar 2024 //
GLOBENEWSWIRE
Madrigal Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
28 Feb 2024 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
21 Feb 2024 //
GLOBENEWSWIRE
Madrigal Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom
08 Feb 2024 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 Feb 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
29 Jan 2024 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22 Jan 2024 //
GLOBENEWSWIRE
Madrigal says it`s `well on the way` to potential NASH launch
11 Jan 2024 //
ENDPTS
Madrigal Presents Five Health Economics Outcomes Research Abstracts
04 Jan 2024 //
GLOBENEWSWIRE
Madrigal to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22 Dec 2023 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27 Nov 2023 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
21 Nov 2023 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
15 Nov 2023 //
GLOBENEWSWIRE
Madrigal says new data show resmetirom has `broad` effects in NASH
11 Nov 2023 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
10 Nov 2023 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial
10 Nov 2023 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Madrigal Announces Participation at Three Upcoming Investor Conferences
02 Nov 2023 //
GLOBENEWSWIRE
Madrigal Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12 Oct 2023 //
GLOBENEWSWIRE
Madrigal raises $500M for NASH drug launch, discloses cyberattack
29 Sep 2023 //
ENDPTS
